

Relationship Between Elevated Morning Blood Pressure Surge, Uric Acid, and Cardiovascular Outcomes in Hypertensive Patients

Osman Turak, MD;¹ Baris Afsar, MD;² Firat Ozcan, MD;¹ Ugur Canpolat, MD;¹ Enis Grbovic, MD;¹ Mehmet Ali Mendi, MD;¹ Fatih Oksuz, MD;¹ Dimitrie Siritopol, MD;³ Adrian Covic, MD;³ Mustafa Caliskan, MD;⁴ Kim McFann, PhD;⁵ Richard J. Johnson, MD;⁵ Mehmet Kanbay, MD⁶

From the Department of Cardiology, Türkiye Yüksek İhtisas Education and Research Hospital, Ankara, Turkey;¹ Division of Nephrology, Department of Medicine, Konya Numune State Hospital, Konya, Turkey;² Department of Nephrology, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania;³ Department of Cardiology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey;⁴ Division of Renal Diseases and Hypertension, University of Colorado, Denver, CO;⁵ and Division of Nephrology, Department of Medicine, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey⁶

Early morning blood pressure surge (MBPS) is a risk factor for cardiovascular events (CVEs), but the relationship with uric acid is not well understood. The authors aimed to determine the association between MBPS and increased uric acid and the effect of elevated MBPS and uric acid combination on CVEs. A total of 921 patients underwent 24-hour ambulatory blood pressure monitoring and were followed for a median of 40 months. During this period,

103 (11.2%) CVEs occurred. There was a significant relationship between increasing quartiles of serum uric acid level and increasing values of MBPS ($P < .0001$). Patients in the highest quartile stratified by elevated MBPS and serum uric acid level had a 3.55 odds of major CVE compared with patients in the lowest quartile. Serum uric acid is associated with MBPS and development of new CVEs. *J Clin Hypertens (Greenwich)*. 2014;16:530–535. ©2014 Wiley Periodicals, Inc.

Blood pressure (BP) is significantly elevated upon awakening, a phenomenon recognized as the morning blood pressure surge (MBPS). Usually this indicates a normal physiological response to changes in physical activity and is a constitutive part of the circadian BP rhythm.¹ However, BP values above the MBPS threshold are associated with target organ damage, including left ventricular hypertrophy, proteinuria, and stroke.^{2,3} Various factors are associated with increased MBPS, including environmental factors,⁴ age and sex,^{5,6} physical activity,⁷ sympathetic nervous tone,⁸ renin-angiotensin system,⁹ arterial stiffness,¹⁰ nondipping status,¹¹ and endothelial dysfunction.¹² However, the mechanisms accounting for MBPS remain conjectural and the exact etiopathogenic mechanisms are not fully known.¹³

An elevated serum uric acid (SUA) level is strongly associated with hypertension.¹⁴ An elevated SUA level predicts the development of hypertension and correlate with BP, especially for nondipping BP.^{15,16} Experimental hyperuricemia in rats also results in raised BP, and the mechanism has been shown to be caused by the induction of oxidative stress,¹⁷ endothelial dysfunction, and activation of the renin-angiotensin system,¹⁸ coupled with subtle microvascular and inflammatory changes in the kidney.¹⁹ Pilot studies have also reported that lowering uric acid level can result in improvement

in BP in both adolescents and adults with hyperuricemia.^{20,21} Since SUA peaks in the early morning,²² we hypothesized that morning SUA might relate to the early MBPS.

Thus, we designed this study to investigate (1) whether SUA and MBPS are related to each other and (2) the role of elevated SUA level and MBPS, single or in combination, for major cardiovascular events (MACEs) including death, stroke or transient ischemic attack, and cardiac events (sudden death, fatal and nonfatal myocardial infarction, and coronary revascularization).

MATERIALS AND METHODS

Study Population

In this observational cohort study we enrolled a total of 921 consecutive patients who visited a outpatient hypertension clinic and underwent 24-hour ambulatory BP monitoring (ABPM) using validated devices between January 2008 and December 2011. All included patients had essential hypertension, either untreated or taking antihypertensive therapy. During each ABPM recording, patients were required to continue their usual daily activities, avoiding only unusual physical exercises or behavioral challenges, and to mark in a diary their main activities, including the time of meals, bed rest, or sleep and awakening times. Patients with chronic liver disease; chronic kidney disease (estimated Chronic Kidney Disease [CKD] Epidemiology Collaboration [CKD-EPI] glomerular filtration rate [GFR] < 60 mL/min/1.73 m²); obvious ongoing illness (eg, malignancy or infection) at baseline; history of gout, stroke (including transient ischemic attacks), arrhythmias (including

Address for correspondence: Mehmet Kanbay, MD, Sağlık Bakanlığı İstanbul Medeniyet Üniversitesi Goztepe Eğitim ve Araştırma Hastanesi, Nefroloji Bilim Dalı, Kadıköy, İstanbul 03490, Turkey
E-mail: drkanbay@yahoo.com

Manuscript received: February 16, 2014; **revised:** May 1, 2014; **accepted:** May 8, 2014
DOI: 10.1111/jch.12359

atrial fibrillation), obstructive sleep apnea, and heavy alcohol intake; night workers and patients who were taking medications known to influence SUA levels (eg, allopurinol, nonsteroidal anti-inflammatory drugs, vitamin use) were excluded from the cohort. Estimated GFR (eGFR) were calculated via the CKD-EPI equation. The study complied with the Declaration of Helsinki, the study protocol was approved by the Yuksek Ihtisas Education, and Research Hospital ethics committee and informed consent was obtained from all participants.

Patients' blood tests and clinical data collection were performed on the day of application of ABPM device. All blood samples were obtained from patients in the morning after 12 hours of fasting for measurement of SUA, fasting plasma glucose (FPG), serum albumin, total serum cholesterol (TC), triglycerides (TGs), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol. Diabetes mellitus was defined according to international guidelines. Smokers were defined as current smokers. Body mass index was calculated as weight (kg)/height (m²).

24-Hour ABPM

The noninvasive 24-hour ABPM reading device (Mobil-O-Graph; IEM GmbH, Stolberg, Germany) used has been described elsewhere.²³ Briefly, the readings were recorded at 20- and 30-minute intervals in the daytime and at nighttime, respectively. The respective daytime and nighttime hours were defined using certain time intervals, which ranged from 6 AM to 10 PM and from 10 PM to 6 AM. Sleep and wake periods were determined on the basis of diary activity reports. Interactive software was utilized to assess the recordings. Any patient lacking $\geq 20\%$ of the measurements was excluded from the study. The mean values of daytime, nighttime, and 24-hour systolic BP (SBP) and diastolic BP (DBP) were calculated for each patient on the basis of hourly averages of ambulatory BP recordings. We defined morning BP surge as the morning SBP (averaged SBP for 2 hours just after waking up) minus the lowest nocturnal SBP by using ABPM after the run-in period (sleep through morning surge as suggested by Kario and colleagues).²⁴

Participants who showed a nocturnal fall of $\geq 10\%$ in SBP were considered dippers. Likewise, a patient whose nocturnal SBP fell by $< 10\%$ or even rose was defined as a nondipper. Office SBP and DBP values were also recorded. Office BP measurements were performed by the same person, following the guidelines of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure on at least two separate occasions on different days.²⁵

Follow-Up and Endpoints

The patients' medical records or other source documents were reviewed periodically after performing the 24-hour ABPM for the occurrence of cardiovascular

outcomes. All included patients were followed up for time-to-event analysis until occurrence of MACEs including death, stroke or transient ischemic attack, and cardiac events (sudden death, fatal and nonfatal myocardial infarction, and coronary revascularization). MACEs were recorded by reviewing outpatient clinic visits in the medical records and telephone contact if such information was not available. We also checked deaths from the national death report system regularly (www.obs.gov.tr).

Statistical Analysis

Sex-specific quartiles of uric acid were defined as follows for men: quartile 1: ≤ 4.8 mg/dL; quartile 2: 4.9–5.4; quartile 3: 5.5–6.4; and quartile 4: > 6.4 ; and for women: quartile 1: ≤ 4.8 mg/dL; quartile 2: 4.9–5.2; quartile 3: 5.5–6.0; and quartile 4: > 6.0 . Analysis of variance with Tukey-Kramer *P*-value adjustments were used to compare characteristics across quartiles of uric acid. Adjusted *P* values $< .05$ were considered significant. Chi-square or Fisher exact test were used to test categorical variables across quartiles of uric acid. Cox regression was used to determine the relationship of MBPS, uric acid, and sex-specific quartiles of uric acid to the hazard of MACEs. Results are reported as hazard ratio (HR) (95% confidence interval [CI]). *P* $< .05$ was considered significant. HR represents a 1 unit change in continuous variables; thus, the HR for uric acid as a continuous variable is the HR for a 1-mg/dL increase in uric acid.

RESULTS

Data regarding uric acid, MBPS, and MACEs were available in 921 patients, of whom 103 (11.2%) had MACEs. There were 420 (45.6%) women and 501 (54.4%) men. A total of 160 patients (17.4%) had diabetes, 204 (22.2%) had a history of smoking, 372 (40.4%) were taking antihypertensive medications, 8 (8.7%) had a previous history of coronary heart disease, 14 (1.5%) had peripheral artery disease (PAD), and 10 (1.09%) had aortic aneurysm. Sex-specific quartiles of uric acid were calculated. The fourth quartile of uric acid was associated with higher TGs, MBPS, mean SBP, daytime SBP, daytime DBP, nighttime SBP, nighttime DBP, office SBP, office DBP, higher creatinine, glucose, and white blood cell count, but lower percentage of nighttime fall in SBP and DBP (Table I). Patients in quartile 4 were also older than those in the first and second quartiles of uric acid. Those in quartile 4 had a higher percentage of diabetes and MACEs than the other quartiles (Table II). Overall, mean MBPS was 37.4 ± 9.2 mm Hg and mean uric acid was 5.6 ± 1.0 . MBPS was significantly lower in patients in the first quartile of uric acid compared with those in the second quartile (*P* = .0007), third quartile (*P* $< .0001$), and fourth quartile (*P* $< .0001$). In addition, the values of MBPS were significantly increased in patients across the quartiles of SUA (*P* $< .0001$).

TABLE I. Characteristics of the Study Population According to Sex-Specific Quartiles of Uric Acid

Variable	Means±SD and P Values				P Value
	Quartile 1	Quartile 2	Quartile 3	Quartile 4	
Age, y	56.9±12.2 ^a	55.4±12.2 ^a	58.7±13.3	61.6±12.8	<.001
HDL cholesterol, mg/dL	45.9±13.1	46.6±12.6	45.1±12.1	44.0±11.6	.128
LDL cholesterol, mg/dL	124.9±28.6	121.9±26.3	130.2±32.9	126.6±33.7	.028
Triglycerides, mg/dL	147.0±55.2 ^a	146.6±66.5 ^a	166.4±86.0	172.8±75.5	<.001
Morning BP surge	33.3±7.1 ^a	36.3±8.7 ^a	40.0±9.6	40.9±9.6	<.001
Systolic BP, mm Hg	135.6±9.8 ^a	137.3±10.1 ^a	138.7±10.8	141.5±11.2	<.001
Diastolic BP, mm Hg	88.0±8.1	89.2±7.9	89.6±9.7	89.3±9.5	.187
Day systolic BP, mm Hg	138.8±9.8 ^a	140.2±10.2 ^b	142.0±11.0	144.3±11.0	<.001
Day diastolic BP, mm Hg	90.5±7.9	91.4±7.6	92.0±8.8	91.6±9.0	.252
Night systolic BP, mm Hg	124.7±13.1 ^a	127.7±14.1 ^b	128.6±15.0	133.2±15.7	<.001
Night diastolic BP, mm Hg	78.2±9.1	80.8±10.3	80.1±11.3	81.8±11.3	.002
Office systolic BP, mm Hg	159.9±15.8 ^b	161.8±16.4	164.4±16.6	164.9±17.1	.004
Office diastolic BP, mm Hg	101.5±15.6	103.0±16.6	106.5±17.2	106.8±18.2	.001
Nighttime fall in systolic BP, %	10.0±7.2 ^b	9.1±7.5	9.2±7.7 ^c	7.3±9.0	.003
Nighttime fall in diastolic BP, %	13.3±8.3 ^b	11.6±8.8	12.8±8.8 ^c	10.2±9.3	.001
Creatinine, mg/dL	0.9±0.1 ^a	0.9±0.2 ^a	0.9±0.2 ^b	1.0±0.2	<.001
eGFR, mL/min/1.73 m ²	94.6±10.8 ^a	94.8±11.3 ^a	91.1±12.3	87.5±11.3	<.001
Glucose, mg/dL	104.1±31.0 ^b	103.6±19.6 ^b	106.2±22.4	112.3±31.1	.002
White blood cells, ×10 ³ /μL	7400±2000	7200±1700 ^c	7600±1600	7700±1800	.016

Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; PAD, peripheral artery disease. ^aP<.001 compared with quartile 4. ^bP<.01 compared with quartile 4. ^cP<.05 compared with quartile 4.

Major Adverse Cardiac Events

In unadjusted Cox regression both MBPS (HR, 1.059; 95% CI, 1.035–1.083; P<.0001) and uric acid (HR, 1.724; 95% CI, 1.443–2.06; P<.0001) were associated with an increased hazard of MACEs. In Cox regression, uric acid as a continuous variable was associated with an increased hazard of a MACE (HR, 1.425) after adjusting for age, sex, diabetes, hypertension status, smoking status, history of aortic aneurysm, coronary heart disease or PAD, TGs, MBPS, and mean SBP (Table III). In Cox regression, the fourth quartile of sex-specific quartiles of uric acid was associated with an increased hazard of a major cardiac event (HR, 2.934) after adjusting for age, sex, diabetes, hypertension status, smoking status, history of aortic aneurysm, coronary heart disease or PAD, TGs, MBPS, and mean

SBP (Table IV). In addition, uric acid was still significant after further adjusting for eGFR measured by the the CKD-EPI equation (Table V and Table VI).

DISCUSSION

In the current study, we tested the hypothesis that MBPS and elevated SUA levels are related with each other and with MACE in a large cohort of hypertensive patients without CKD. Our primary findings were that: (1) both MBPS and SUA level were associated with MACE, (2) SUA level and MBPS were associated with each other, and (3) patients in the highest quartile stratified by elevated MBPS and SUA level had a 3.55 odds of MACE compared with those in the lowest quartile. To the best of our knowledge, the last finding is novel and has not been demonstrated before.

TABLE II. Characteristics of the Study Population According to Quartiles of Serum Uric Acid

Variable	Quartile 1 (n=239) (%)	Quartile 2 (n=259) (%)	Quartile 3 (n=213) (%)	Quartile 4 (n=210) (%)	P Value
Female sex	110 (46.0)	118 (45.6)	95 (44.6)	97 (46.2)	.987
Diabetes	26 (10.9)	45 (17.4)	35 (16.4)	54 (25.7)	.001
Smoking	48 (20.1)	54 (20.9)	53 (24.9)	49 (23.3)	.585
Hypertension	92 (38.5)	97 (37.5)	94 (44.1)	89 (42.4)	.412
Coronary artery disease	19 (8.0)	24 (9.3)	17 (8.0)	20 (9.5)	.375
PAD	5 (2.1)	5 (1.9)	3 (1.4)	1 (0.5)	
Aortic aneurysm	2 (0.8)	0 (0)	3 (1.4)	5 (2.4)	
MACE	9 (3.8)	8 (3.1)	36 (16.9)	50 (23.8)	<.0001

Abbreviations: MACE, major adverse cardiac event; PAD, peripheral artery disease.

TABLE III. Cox Regression of Major Adverse Cardiac Events on Uric Acid as a Continuous Variable

Variable	HR (95% CI)	P Value
Age, y	1.06 (1.04–1.08)	<.0001
Female sex	1.34 (0.89–2.02)	.160
Diabetes	2.85 (1.87–4.35)	<.0001
Hypertension	0.74 (0.48–1.13)	.167
Smoking	1.47 (0.94–2.32)	.095
Previous aortic aneurysm	2.77 (1.22–6.28)	.015
Previous coronary artery disease	2.00 (1.09–3.66)	.023
PAD	1.47 (0.19–11.51)	.708
HDL cholesterol, mg/dL	0.98 (0.96–0.99)	.014
LDL cholesterol, mg/dL	1.01 (1.00–1.01)	.006
Triglycerides, mg/dL	0.99 (0.99–1.00)	.445
MBPS	1.06 (1.04–1.08)	<.0001
Systolic BP, mm Hg	1.02 (1.00–1.04)	.047
Uric acid	1.43 (1.18–1.72)	.0002

Abbreviations: BP, blood pressure; CI, confidence interval; HDL, high-density lipoprotein cholesterol; HR, hazard ratio; LDL, low-density lipoprotein cholesterol; MBPS, morning blood pressure surge; PAD, peripheral artery disease.

TABLE IV. Cox Regression of Major Adverse Cardiac Events on Uric Acid as a Categorical Variable

Variable	HR (95% CI)	P Value
Age, y	1.06 (1.04–1.08)	<.0001
Female sex	1.23 (0.82–1.84)	.324
Diabetes	2.88 (1.86–4.39)	<.0001
Hypertension	0.70 (0.45–1.08)	.102
Smoking	1.48 (0.94–2.34)	.089
Previous aortic aneurysm	2.76 (1.21–6.28)	.015
Previous coronary artery disease	2.08 (1.14–3.78)	.016
PAD	1.17 (0.15–9.38)	.882
HDL, mg/dL	0.98 (0.96–0.99)	.020
LDL, mg/dL	1.01 (1.00–1.01)	.009
Triglycerides, mg/dL	0.99 (0.99–1.00)	.399
MBPS	1.05 (1.03–1.08)	<.0001
Systolic BP, mm Hg	1.02 (1.00–1.04)	.054
Quartile 2 vs quartile 1	0.68 (0.26–1.80)	.438
Quartile 3 vs quartile 1	2.09 (0.96–4.58)	.063
Quartile 4 vs quartile 1	2.93 (1.38–6.24)	.005

Abbreviations: BP, blood pressure; CI, confidence interval; HDL, high-density lipoprotein cholesterol; HR, hazard ratio; LDL, low-density lipoprotein cholesterol; MBPS, morning blood pressure surge; PAD, peripheral artery disease.

Previous studies have reported conflicting results regarding the relationship between MBPS and cardiovascular outcomes. While some studies have shown a positive association,^{24,26} others described a negative association.^{11,27} In this study, we evaluated the relationship of morning uric acid levels with early MBPS and demonstrated that SUA level and MBPS were

TABLE V. Cox Regression of Major Adverse Cardiac Events on Uric Acid as a Continuous Variable With eGFR

Variable	HR (95% CI)	P Value
Age, y	1.04 (1.01–1.07)	.004
Female sex	1.26 (0.83–1.91)	.277
Diabetes	2.74 (1.78–4.21)	<.0001
Hypertension	0.78 (0.51–1.19)	.258
Smoking	1.44 (0.91–2.28)	.115
Previous aortic aneurysm	2.83 (1.23–6.47)	.014
Previous coronary artery disease	2.08 (1.14–3.78)	.017
PAD	1.38 (0.17–10.82)	.754
HDL cholesterol, mg/dL	0.97 (0.96–0.99)	.020
LDL cholesterol, mg/dL	1.01 (1.01–1.01)	.007
Triglycerides, mg/dL	0.99 (0.99–1.01)	.399
MBPS	1.06 (1.04–1.08)	<.0001
Systolic BP, mm Hg	1.02 (0.99–1.04)	.072
eGFR, mL/min/1.73 m ²	0.97 (0.95–1.01)	.132
Uric acid	1.38 (1.15–1.67)	.0006

Abbreviations: BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; MBPS, morning blood pressure surge; PAD, peripheral artery disease.

correlated with each other. In this regard, Kario and colleagues²⁴ previously reported that patients in the highest quartile of SUA levels had higher MBPS. Another study demonstrated that MBPS and SUA level are correlated,²⁸ but there was no risk stratification with special respect to cardiovascular outcomes. Although no cause and effect relationship can be suggested due to the observational design of our study, we hypothesize that SUA level may play a direct role in the elevation of MBPS.

Why would an elevated SUA level be related to an increase in MBPS? One mechanism could be related to the known opposing effects of uric acid and nitric oxide (NO) in the circadian rhythm.²⁹ During early morning hours, serum NO falls while uric acid rises. While not directly tested in this study, hyperuricemia is strongly associated with endothelial dysfunction and uric acid has been shown to reduce endothelial NO bioavailability via multiple mechanisms, including direct scavenging, induction of oxidants, or altering arginine transport or metabolism.^{18,30–33} Lowering uric acid has also been reported to improve endothelial function in humans.^{20,21} Thus, a role of uric acid on NO and circadian rhythm is possible.

Other mechanisms may also be operative, including potential activation of the renin-angiotensin system³⁴ or induction of oxidative stress,¹⁷ both of which are associated with MBPS.^{35,36} Plasma renin activity, angiotensin II, and aldosterone levels are all increased before awakening and then further increase after awakening.^{9,37} One of the important aspects of the MBPS is the dependency of measurements on dipping/nondipping status,^{11,38} although, at least in some

TABLE VI. Cox Regression of Major Adverse Cardiac Events on Uric Acid as a Categorical Variable With eGFR

Variable	HR (95% CI)	P Value
Age, y	1.04 (1.01–1.07)	.006
Female sex	1.16 (0.77–1.76)	.471
Diabetes	2.76 (1.80–4.24)	<.0001
Hypertension	0.74 (0.48–1.14)	.171
Smoking	1.45 (0.92–2.29)	.114
Previous aortic aneurysm	2.83 (1.23–6.51)	.014
Previous coronary artery disease	2.15 (1.18–3.90)	.012
PAD	1.14 (0.14–9.14)	.901
HDL cholesterol, mg/dL	0.97 (0.96–0.99)	.029
LDL cholesterol, mg/dL	1.01 (1.02–1.01)	.011
Triglycerides, mg/dL	0.99 (0.99–1.02)	.361
MBPS	1.05 (1.03–1.07)	<.0001
Systolic BP, mm Hg	1.02 (0.99–1.04)	.082
eGFR, mL/min/1.73 m ²	0.97 (0.95–1.01)	.142
Quartile 2 vs quartile 1	0.67 (0.26–1.78)	.430
Quartile 3 vs quartile 1	1.96 (0.89–4.32)	.092
Quartile 4 vs quartile 1	2.75 (1.29–5.88)	.008

Abbreviations: BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; MBPS, morning blood pressure surge; PAD, peripheral artery disease.

studies, the association between MBPS and outcomes is independent of dipping and nondipping status.²⁴

STUDY LIMITATIONS

Our study has some limitations. Firstly, the cross-sectional design precludes us to conclude cause and effect relationships. Secondly, the measurements were performed once and the reproducibility of MBPS is questionable in some studies.^{39,40} Thirdly, we relied on diaries, and actual sleeping and waking periods were not measured by more objective measures such as actigraphy. Fourthly, physical activity of the patients was not assessed. Lastly, the mean of MBPS was relatively high in our study. Although we don't know the exact causes of this, it may be caused by a high number of women with diabetes in our cohort.

CONCLUSIONS

We demonstrated for the first time that patients stratified for both elevated SUA level and MBPS have increased MACEs compared with other patients. Studies are needed to determine whether specific medications that decrease uric acid will translate into lower MBPS and improved cardiovascular outcomes.

Financial Support: None.

Disclosure: None.

Conflict of Interest: Dr Johnson is listed as an inventor on a patent for allopurinol to treat essential hypertension and is also an inventor on patent

applications related to lowering uric acid in the prevention or treatment of hypertension, insulin resistance, and diabetic nephropathy. He also serves on the scientific board of Amway. All other authors declared no competing interests and had access to the data and played a role in writing this manuscript.

References

- Gosse P, Lasserre R, Minifie C, Lemetayer P, Clementy J. Blood pressure surge on rising. *J Hypertens*. 2004;22:1113–1118.
- Kario K, White WB. Early morning hypertension: what does it contribute to overall cardiovascular risk assessment? *J Am Soc Hypertens*. 2008;2:397–402.
- Yano Y, Kario K. Nocturnal blood pressure, morning blood pressure surge, and cerebrovascular events. *Curr Hypertens Rep*. 2012;14:219–227.
- Pickering TG. The influence of daily activity on ambulatory blood pressure. *Am Heart J*. 1988;116:1141–1145.
- Sun N, Xi Y, Jing S, Lu X. Morning blood pressure surge varies with age and gender in hypertensive individuals. *Int J Cardiol*. 2009;135:272–273.
- Li Y, Thijs L, Hansen TW, et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. *Hypertension*. 2010;55:1040–1048.
- Leary AC, Struthers AD, Donnan PT, MacDonald TM, Murphy MB. The morning surge in blood pressure and heart rate is dependent on levels of physical activity after waking. *J Hypertens*. 2002;20:865–870.
- Okada Y, Galbreath MM, Shibata S, et al. Morning blood pressure surge is associated with arterial stiffness and sympathetic baroreflex sensitivity in hypertensive seniors. *Am J Physiol Heart Circ Physiol*. 2013;305:H793–H802.
- Brandenberger G, Follenius M, Goichot B, Saini J, Spiegel K, Ehrhart J, Simon C. Twenty-four-hour profiles of plasma renin activity in relation to the sleep-wake cycle. *J Hypertens*. 1994;12:277–283.
- Sanchez Gelos DF, Otero-Losada ME, Azzato F, Milei J. Morning surge, pulse wave velocity, and autonomic function tests in elderly adults. *Blood Press Monit*. 2012;17:103–109.
- Verdecchia P, Angeli F, Mazzotta G. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. *Hypertension*. 2012;60:34–42.
- Otto ME, Svatikova A, Barretto RB, et al. Early morning attenuation of endothelial function in healthy humans. *Circulation*. 2004;109:2507–2510.
- Suh M, Barksdale DJ, Logan JG. Morning blood pressure surge and nighttime blood pressure in relation to nocturnal sleep pattern and arterial stiffness. *J Cardiovasc Nurs*. 2013;29:E10–E17.
- Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. *Heart*. 2013;99:759–766.
- Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. *Arthritis Care Res (Hoboken)*. 2011;63:102–110.
- Turak O, Ozcan F, Tok D, et al. Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. *J Clin Hypertens (Greenwich)*. 2013;15:7–13.
- Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. *Am J Physiol Renal Physiol*. 2008;295:F1134–F1141.
- Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. *J Hypertens*. 2010;28:1234–1242.
- Kanbay M, Sanchez-Lozada LG, Franco M, et al. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. *Nephrol Dial Transplant*. 2011;26:430–437.
- Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. *Clin J Am Soc Nephrol*. 2011;6:1887–1894.
- Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. *Int Urol Nephrol*. 2007;39:1227–1233.
- Kanabrocki EL, Ryan MD, Hermida RC, et al. Altered circadian relationship between serum nitric oxide, carbon dioxide, and uric acid in multiple sclerosis. *Chronobiol Int*. 2004;21:739–758.
- Franssen PM, Imholz BP. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. *Blood Press Monit*. 2010;15:229–231.

24. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation*. 2003;107:1401–1406.
25. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507–520.
26. Yano Y, Hoshida S, Inokuchi T, Kanemaru Y, Shimada K, Kario K. Association between morning blood pressure surge and cardiovascular remodeling in treated elderly hypertensive subjects. *Am J Hypertens*. 2009;22:1177–1182.
27. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *JAMA*. 1999;282:539–546.
28. Tutal E, Sayin B, Ertugrul DT, Ibis A, Sezer S, Ozdemir N. Is there a link between hyperuricemia, morning blood pressure surge, and non-dipping blood pressure pattern in metabolic syndrome patients? *Int J Nephrol Renovasc Dis*. 2013;6:71–77.
29. Kanabrocki EL, Third JL, Ryan MD, et al. Circadian relationship of serum uric acid and nitric oxide. *JAMA*. 2000;283:2240–2241.
30. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. *Kidney Int*. 2005;67:1739–1742.
31. Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. *Am J Physiol Cell Physiol*. 2008;295:C1183–C1190.
32. Schwartz IF, Grupper A, Chernichovski T, et al. Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. *J Vasc Res*. 2011;48:252–260.
33. Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid. *Nucleosides, Nucleotides Nucleic Acids*. 2008;27:967–978.
34. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. *Kidney Int*. 2004;66:1465–1470.
35. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. *Hypertension*. 2010;56:765–773.
36. Maeda K, Yasunari K, Watanabe T, Nakamura M. Oxidative stress by peripheral blood mononuclear cells is increased in hypertensives with an extreme-dipper pattern and/or morning surge in blood pressure. *Hypertens Res*. 2005;28:755–761.
37. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. *N Engl J Med*. 1991;325:986–990.
38. Israel S, Israel A, Ben-Dov IZ, Bursztyn M. The morning blood pressure surge and all-cause mortality in patients referred for ambulatory blood pressure monitoring. *Am J Hypertens*. 2011;24:796–801.
39. Wang MY, Huang CJ, Chang NC, Tsai PS. Reproducibility of morning blood pressure surge and its relation to blood pressure reactivity. *Clin Exp Hypertens*. 2007;29:357–368.
40. Wizner B, Dechering DG, Thijs L, et al. Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. *J Hypertens*. 2008;26:1328–1335.